The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine
Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced. The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
37
All patients will undergo this intervention on one of two study days
All patients will undergo this intervention on one of two study days
All patients will undergo this intervention on both study days
DanishHC
Glostrup Municipality, Denmark
Incidence of migraine
Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine
Time frame: From 0 to 12 hours after infusion
Effect of Sumatriptan
Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")
Time frame: From 0 to 12 hours after infusion
Severity of flushing
Facial skin blood flow (flushing) will be measured by laser doppler flowmetry to evaluate the severity of PACAP38-induced flushing with and without sumatriptan-treatment
Time frame: From 0 to 4 hours after infusion
Facial temperature
PACAP38-induced temperature changes with and without sumatriptan-treatment measured by infrared thermography
Time frame: From 0 to 4 hours after infusion
Superficial temporal artery diameter
Superficial temporal artery diameter after PACAP38 with and without sumatriptan-treatment measured by ultrasound
Time frame: From 0 to 4 hours after infusion
Severity of headache
Severity of PACAP38-induced headache will be rated on a numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")
Time frame: From 0 to 12 hours after infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.